Profile for European Patent Office Patent: 2822954
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Netherlands | 300947 | ⤷ Start Trial |
| Germany | 122018000094 | ⤷ Start Trial |
| Luxembourg | LUC00083 | ⤷ Start Trial |
| Denmark | CA 2018 00029 | ⤷ Start Trial |
| Lithuania | PA2018511 | ⤷ Start Trial |
| Austria | 33/2018 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 2822954
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| 9,216,996 | Dec 19, 2033 | Gilead Sciences Inc | BIKTARVY | bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate |
| 9,732,092 | Dec 19, 2033 | Gilead Sciences Inc | BIKTARVY | bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
